Quantcast

New Trials


#1

Here are some trials that were newly posted on clinicaltrials.gov in the last 2 weeks. Most are not recruiting yet and I have no idea how long it will take before they start recruiting. The names of the drugs are in bold and I added some information that may help decide whether the trial is interesting or not.

Lorvotuzumab Mertansine (not yet recruiting)

Target: CD56

https://clinicaltrials.gov/ct2/show/NCT02452554

Relevance:

http://www.ncbi.nlm.nih.gov/pubmed/7678094

Olaratumab (not yet recruiting)

Target: PDGFRα

https://clinicaltrials.gov/ct2/show/NCT02451943

Significance:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432680/

Anlotinib (currently recruiting in China)

Target: RTK including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3)

https://clinicaltrials.gov/ct2/show/NCT02449343

PM01183 (not yet recruiting)

DNA minor groove covalent binder

https://clinicaltrials.gov/ct2/show/NCT02448537

Relevance:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998690/

PF-05082566 and KW-0761(not yet recruiting)

Immunotherapy

Target: 4-1bb

Target: Anti-CCR4 monoclonal antibody

https://clinicaltrials.gov/ct2/show/NCT02444793

TAS-119 (recruiting in UK and Netherlands)

Target: Aurora kinase A inhibitor

https://clinicaltrials.gov/ct2/show/NCT02448589

Relevance:

http://www.ncbi.nlm.nih.gov/pubmed/22244830


#2

Thank you, Elodie, that is a good number. It's encouraging.


#3

Thanks so much now i can research something